We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized...
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated...
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage...
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cyclesPowerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular...
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announced that it has received approval To...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.45 | 13.8461538462 | 3.25 | 3.94 | 3 | 25679 | 3.51092887 | CS |
4 | -1.09 | -22.7557411273 | 4.79 | 4.8 | 3 | 15268 | 3.69136824 | CS |
12 | -3.08 | -45.4277286136 | 6.78 | 7.45 | 3 | 8504 | 4.34325916 | CS |
26 | -4.15 | -52.8662420382 | 7.85 | 8.65 | 3 | 6081 | 5.09021334 | CS |
52 | -6.1 | -62.2448979592 | 9.8 | 10.45 | 3 | 5867 | 7.04482115 | CS |
156 | -7.14 | -65.8671586716 | 10.84 | 15.05 | 3 | 7487 | 8.37127622 | CS |
260 | -7.14 | -65.8671586716 | 10.84 | 15.05 | 3 | 7487 | 8.37127622 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions